Instrument Inactif

Communiqués Pieris Pharmaceuticals

Actions

PIRS

US7207952026

Communiqués

16/12/24	Palvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and Concurrent Private Placement of $78.9 Million	AQ
16/12/24	Pieris Pharmaceuticals : Palvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and Concurrent Private Placement of $78.9 Million Form 8 K	PU
20/11/24	PIERIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pieris Pharmaceuticals, Inc. - PIRS	BU
13/11/24	Pieris Pharmaceuticals: Q3 Earnings Snapshot	AQ
07/11/24	Palvella Therapeutics Announces First Patient Dosed in SELVA Phase 3 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations	AQ
17/10/24	Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer	AQ
16/10/24	Palvella Therapeutics Announces Presentations at the 12th Pediatric Dermatology Research Alliance Annual Conference	AQ
03/10/24	Pieris Pharmaceuticals : Palvella Therapeutics Awarded Up to $2.6 million Grant from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development to Support Phase 3 Single Arm, Baseline Controlled Trial in Microcystic Lymphatic Malformations Form 8 K	PU
15/08/24	Pieris Pharmaceuticals: Q2 Earnings Snapshot	AQ
25/07/24	Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement	AQ
25/07/24	PIERIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pieris Pharmaceuticals, Inc. - PIRS	BU
15/05/24	Pieris Pharmaceuticals: Q1 Earnings Snapshot	AQ
22/04/24	Pieris Pharmaceuticals Announces 1-for-80 Reverse Stock Split	AQ
18/04/24	Pieris Pharmaceuticals : Announces 1-for-80 Reverse Stock Split - Form 8-K	PU
28/03/24	Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potential	AQ
27/03/24	Pieris Pharmaceuticals : Announces Strategy to Maximize Partnered Milestone and Royalty Potential - Form 8-K	PU
14/11/23	Pieris Pharmaceuticals: Q3 Earnings Snapshot	AQ
18/08/23	Pieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific	AQ
18/07/23	Pieris Pharmaceuticals : Provides Strategic Update and Announces Restructuring - Form 8-K	PU
21/06/23	Pieris Pharmaceuticals : Announces AstraZeneca Discontinuation of Phase 2a Trial of Elarekibep (PRS-060/AZD1402) Due to New Non-Clinical Safety Findings From 13-week Toxicology Study - Form 8-K	PU
21/06/23	PIERIS PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
08/06/23	PIERIS PHARMACEUTICALS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
19/05/23	PIERIS PHARMACEUTICALS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	AQ
10/05/23	PIERIS PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
10/05/23	Pieris Pharmaceuticals: Q1 Earnings Snapshot	AQ